Many patients with diabetes say that the inconvenience and discomfort of constant therapeutic vigilance, particularly multiple daily insulin injections, has as much impact on their quality of life as the burden of intermediate complications, researchers from the University of Chicago report in the October 2007 issue of Diabetes Care.
Researchers at the University of Illinois at Chicago College of Medicine have identified a new molecular target in the process of blood clot formation, which seems to reduce clotting without excessive bleeding, the common side-effect of anti-clotting agents.
Preliminary research suggests that in children at increased risk for type 1 diabetes, dietary intake of omega-3 fatty acids was associated with a reduced risk of pancreatic islet autoimmunity, which is linked to the development of diabetes, according to an article in the Sept. 26 issue of JAMA.
Breath-analysis testing may prove to be an effective, noninvasive method for monitoring blood sugar levels in diabetes, according to a University of California, Irvine study.
Recent investigations of medications, diet and the molecular understanding of prostate cancer are defining potential prevention strategies for the disease, and herald a new stage in the management of this cancer, according to a new review.
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) and Eli Lilly and Company (NYSE: LLY) announced baseline data from INSTIGATE, a 24-month study presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Amsterdam, The Netherlands.
The obesity epidemic has spawned not just diabetes, but another serious public health problem: a surge in fatty liver disease, which can lead to cirrhosis and liver failure. Now, research suggests that limiting consumption of high-glycemic-index carbohydrates can prevent the condition in mice. A clinical trial is now testing this idea in overweight adolescents, as well as the possibility of reversing fatty liver disease through diet.
Biomedical engineers at the University of Texas School of Health Information Sciences at Houston have announced pre-clinical test results in the September issue of the International Journal of Nanomedicine demonstrating the feasibility of a smart particle insulin release system that detects spikes in glucose or blood sugar levels and releases insulin to counteract them
Uncontrolled patients with type 2 diabetes treated with metformin, one of the most prescribed oral medicines for this disease, were four times more likely to achieve recommended blood sugar control levels by adding Galvus® (vildagliptin) to their treatment compared to those who added a placebo, according to new clinical data[1].
The U.S. Food and Drug Administration cleared for marketing a new genetic test that will help physicians assess whether a patient may be especially sensitive to the blood-thinning drug warfarin (Coumadin), which is used to prevent potentially fatal clots in blood vessels.